These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 22140424

  • 1. Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS.
    Goodin DS, Jones J, Li D, Traboulsee A, Reder AT, Beckmann K, Konieczny A, Knappertz V, 16-Year Long-Term Follow-up Study Investigators.
    PLoS One; 2011; 6(11):e22444. PubMed ID: 22140424
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis.
    Goodin DS, Traboulsee A, Knappertz V, Reder AT, Li D, Langdon D, Wolf C, Beckmann K, Konieczny A, Ebers GC, 16-Year Long Term Follow-up Study Investigators.
    J Neurol Neurosurg Psychiatry; 2012 Mar; 83(3):282-7. PubMed ID: 22193561
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B, Jacobs LD.
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The impact of betaplus program on patient treatment satisfaction with interferon beta-1b in multiple sclerosis: Multicentric cross-sectional survey in the western Balkan countries.
    Drulovic J, Cukic M, Grgic S, Dincic E, Raicevic R, Nadj C, Toncev G, Vojinovic S, Mesaros S, Kisic Tepavcevic D, Dujmovic I, Tadic D, Miletic-Drakulic S, Dackovic J, Kostic S, Erakovic J, Sakalas L, Savic D, Suknjaja V, Martinovic V, Maric G, Pekmezovic T.
    Mult Scler Relat Disord; 2017 Jan; 11():56-61. PubMed ID: 28104258
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study.
    Patti F, Penaherrera JN, Zieger L, Wicklein EM.
    BMC Neurol; 2021 Aug 23; 21(1):324. PubMed ID: 34425763
    [Abstract] [Full Text] [Related]

  • 16. Alternative statistical methods for estimating efficacy of interferon beta-1b for multiple sclerosis clinical trials.
    Mieno MN, Yamaguchi T, Ohashi Y.
    BMC Med Res Methodol; 2011 May 26; 11():80. PubMed ID: 21612661
    [Abstract] [Full Text] [Related]

  • 17. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis.
    Shirani A, Zhao Y, Karim ME, Evans C, Kingwell E, van der Kop ML, Oger J, Gustafson P, Petkau J, Tremlett H.
    JAMA; 2012 Jul 18; 308(3):247-56. PubMed ID: 22797642
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis.
    Prosperini L, Mancinelli CR, De Giglio L, De Angelis F, Barletta V, Pozzilli C.
    Mult Scler; 2014 Apr 18; 20(5):566-76. PubMed ID: 23999607
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.